Nifrtimox for Refractory/Relapsed Neuroblastoma & Medulloblastoma

A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma and Relapsed Medulloblastoma

November 22, 2017

  • Clinical Trial Information

    Trial Contact: El-Shami, Jessica

    Trial Phone: 321.841.3837

  • IRB No: 08.051.07

    Principal Investigator: Don E. Eslin, MD

    Sub Investigators: Giusti, Vincent MD; Kelly, Susan MD; Smith, Amy MD; Sutphin, Robert MD; Levy, Alejandro MD

    Phase: Drug: Phase II

    Age Group: Pediatric

    Secondary Protocol No: V0706

    Treatment: Chemotherapy

    Applicable Disease Sites: Neuroblastoma

    Therapies Involved: Drug: Nifurtimox Drug: Cyclophosphamide Drug: Topotecan ID: NCT00601003

  • Objective

    The purpose of this study is to determine whether nifurtimox in combination with chemotherapy are effective in the treatment of neuroblastoma and medulloblastoma.

  • Key Eligibility

    Ages Eligible for Study: up to 21 Years; Genders Eligible for Study: Both; Accepts Healthy Volunteers: No